AEON Biopharma, Inc. AEON
0.13 USD +0.01 (+7.08%)
Regular-session close
0.13 0.00 -0.53%
After hours · Nov 19, 7:18 PM ET
0.1201 Day range 0.1357
0.106 52-week range 1.45
- YTD
- -87.90%
- 1 year
- -85.84%
5D -0.0336 (-19.28%)
- Market cap
- 11.20M
- EPS (ttm)
- -4.39
- Shares out
- 39.97M
- Forward P/E
- -0.84
- YTD return
- -87.90%
- 1-year return
- -85.84%
- 50-day average
- 0.76512
- 200-day average
- 2.58
- Volume
- 759.34K
- Avg volume
- 7.47M
- Open
- 0.1219
- Previous close
- 0.1243
- Day's range
- 0.1201 – 0.1357
- 52-week range
- 0.106 – 1.45
- Beta
- 0.40
- Price target
- 5.00 (+3656.6%)
Key statistics
- Enterprise value
- 32.96M
- Free cash flow
- -24.60M
- Total cash
- 3.44M
- Total debt
- 14.69M
- Short % of float
- 0.72%
Fundamental scorecard
3 of 25 checks passed on AEON’s reported financials
3of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
AEON Revenue — quarterly 0
AEON Net income — quarterly 2.46M
AEON EPS — quarterly 0.01
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.16 | -0.16 | 0.00 | 0.00% |
| Aug 12, 2024 | Jun 1, 2024 | -0.19 | — | — | — |
| Aug 12, 2024 | Jun 1, 2024 | -0.19 | -0.16 | +0.03 | +15.79% |
| May 14, 2024 | Mar 1, 2024 | -0.31 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.31 | -0.28 | +0.03 | +9.68% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 1, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 14, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 10, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 30, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 15, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| May 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About AEON Biopharma, Inc.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- aeonbiopharma.com
News
Why Aytu Biopharma Shares Are Trading Higher By 43%; Here Are 20 Stocks Moving Premarket AEON Biopharma Q3 EPS $0.01 Beats $(0.08) Estimate
AEON Biopharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Aeon Strategies Ltd. Provides Bi-Weekly MCTO Status Update AEON Biopharma Submits IND To FDA For Comparative Pharmacodynamic Study Of ABP-450
AEON Biopharma Submits IND for Comparative Pharmacodynamic Study of ABP-450
AEON STRATEGIES LTD. Provides Update on Anticipated Late Filing of Annual Financial Statements
Aeon Strategies Ltd. Announces Anticipated Late Filing of Annual Financial Statements and Application for Management Cease Trade Order
AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450
AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX®
Your note
Sign in to keep a note on AEON — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CARTER ERIC G | Director | Stock Award(Grant) | Aug 29, 2024 | 36,021 |
| FISCHER JOST | Director | Stock Award(Grant) | Aug 29, 2024 | 96,785 |
| FORTH MARC | Chief Executive Officer | Stock Award(Grant) | Aug 29, 2024 | 750,547 |
| OH CHAD M.D. | Officer | Stock Award(Grant) | Aug 29, 2024 | 292,545 |
| PALMISANO ROBERT J | Director | Stock Award(Grant) | Aug 29, 2024 | 36,021 |
| PRIVETERRA SPONSOR, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jul 20, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Polar Asset Management Partners Inc. | 9.01% | 3,599,918 | 2.09M | Sep 29, 2024 |
| Blue Owl Capital Holdings LP | 8.36% | 3,341,204 | 1.94M | Sep 29, 2024 |
| Vanguard Group Inc | 1.88% | 751,343 | 437.21K | Sep 29, 2024 |
| Formidable Asset Management, Llc | 0.98% | 389,782 | 226.81K | Sep 29, 2024 |
| Blackrock Inc. | 0.66% | 265,150 | 154.29K | Sep 29, 2024 |
| Ikarian Capital, LLC | 0.65% | 257,977 | 150.12K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.04% | 414,900 | 241.43K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.80% | 320,899 | 186.73K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.36% | 145,373 | 84.59K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.14% | 54,417 | 31.66K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.12% | 46,260 | 26.92K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.09% | 35,140 | 20.45K | Oct 30, 2024 |
